Literature DB >> 21738819

Mammalian target of rapamycin: a central node of complex signaling cascades.

Yoh Dobashi1, Yasutaka Watanabe, Chihiro Miwa, Sakae Suzuki, Shinichiro Koyama.   

Abstract

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates cell growth and metabolism in response to diverse external stimuli. In the presence of mitogenic stimuli, mTOR transduces signals that activate the translational machinery and promote cell growth. mTOR functions as a central node in a complex net of signaling pathways that are involved both in normal physiological, as well as pathogenic events. mTOR signaling occurs in concert with upstream Akt and tuberous sclerosis complex (TSC) and several downstream effectors. During the past few decades, the mTOR-mediated pathway has been shown to promote tumorigenesis through the coordinated phosphorylation of proteins that directly regulate cell-cycle progression and metabolism, as well as transcription factors that regulate the expression of genes involved in the oncogenic processes. The importance of mTOR signaling in oncology is now widely accepted, and agents that selectively target mTOR have been developed as anti-cancer drugs. In this review, we highlight the past research on mTOR, including clinical and pathological analyses, and describe its molecular mechanisms of signaling, and its roles in the physiology and pathology of human diseases, particularly, lung carcinomas. We also discuss strategies that might lead to more effective clinical treatments of several diseases by targeting mTOR.

Entities:  

Keywords:  lung cancer; mTOR; molecular targeting therapy; rapamycin

Mesh:

Substances:

Year:  2011        PMID: 21738819      PMCID: PMC3127069     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  115 in total

Review 1.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

Review 2.  mTOR, a new therapeutic target in acute myeloid leukemia.

Authors:  Christian Récher; Cédric Dos Santos; Cécile Demur; Bernard Payrastre
Journal:  Cell Cycle       Date:  2005-11-08       Impact factor: 4.534

3.  Mammalian target of rapamycin regulates expression of β-catenin in hepatocellular carcinoma.

Authors:  Zhenbo Feng; Xuejun Fan; Yang Jiao; Kechen Ban
Journal:  Hum Pathol       Date:  2011-01-15       Impact factor: 3.466

4.  mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.

Authors:  Ghada A Soliman; Hugo A Acosta-Jaquez; Elaine A Dunlop; Bilgen Ekim; Nicole E Maj; Andrew R Tee; Diane C Fingar
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

5.  Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.

Authors:  Lei Fu; Young-Ae Kim; Xuerong Wang; Xiaoyun Wu; Ping Yue; Sagar Lonial; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

6.  Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.

Authors:  Yoh Dobashi; Shioto Suzuki; Hirochika Matsubara; Maiko Kimura; Shunsuke Endo; Akishi Ooi
Journal:  Cancer       Date:  2009-01-01       Impact factor: 6.860

7.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

Authors:  Eric Raymond; Jérôme Alexandre; Sandrine Faivre; Karina Vera; Eric Materman; Joseph Boni; Cathie Leister; Joan Korth-Bradley; Axel Hanauske; Jean-Pierre Armand
Journal:  J Clin Oncol       Date:  2004-05-10       Impact factor: 44.544

8.  Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.

Authors:  Silvia La Monica; Maricla Galetti; Roberta R Alfieri; Andrea Cavazzoni; Andrea Ardizzoni; Marcello Tiseo; Marzia Capelletti; Matteo Goldoni; Sara Tagliaferri; Antonio Mutti; Claudia Fumarola; Mara Bonelli; Daniele Generali; Pier Giorgio Petronini
Journal:  Biochem Pharmacol       Date:  2009-05-07       Impact factor: 5.858

9.  Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.

Authors:  Esther Conde; Barbara Angulo; Moying Tang; Manuel Morente; Juan Torres-Lanzas; Angel Lopez-Encuentra; Fernando Lopez-Rios; Montserrat Sanchez-Cespedes
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

Review 10.  Tor signalling in bugs, brain and brawn.

Authors:  Estela Jacinto; Michael N Hall
Journal:  Nat Rev Mol Cell Biol       Date:  2003-02       Impact factor: 94.444

View more
  47 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

Review 2.  Primary cilia and coordination of receptor tyrosine kinase (RTK) signalling.

Authors:  Søren T Christensen; Christian A Clement; Peter Satir; Lotte B Pedersen
Journal:  J Pathol       Date:  2011-11-21       Impact factor: 7.996

Review 3.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 4.  Novel and emerging targeted-based cancer therapy agents and methods.

Authors:  Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2015-02-09

Review 5.  Autophagy in synaptic development, function, and pathology.

Authors:  Dan-Na Shen; Li-Hui Zhang; Er-Qing Wei; Yi Yang
Journal:  Neurosci Bull       Date:  2015-07-02       Impact factor: 5.203

6.  MYCing and YAPing the escape of tumor cell growth arrest after chronic PI3K/mTOR inhibition.

Authors:  Georgios D Vavougios; Sotirios G Zarogiannis
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 7.  Primary ductal adenocarcinoma of the lacrimal sac: the first reported case.

Authors:  Mitsuaki Ishida; Muneo Iwai; Keiko Yoshida; Akiko Kagotani; Hideaki Kohzaki; Masahiko Arikata; Takeshi Shimizu; Hidetoshi Okabe
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

8.  Gene-ethanol interactions underlying fetal alcohol spectrum disorders.

Authors:  Neil McCarthy; Johann K Eberhart
Journal:  Cell Mol Life Sci       Date:  2014-02-20       Impact factor: 9.261

9.  Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.

Authors:  Linette Castillo-Pichardo; Suranganie F Dharmawardhane
Journal:  Nutr Cancer       Date:  2012       Impact factor: 2.900

Review 10.  Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.